AUTHOR=Cuthbertson Daniel J. , Barriuso Jorge , Lamarca Angela , Manoharan Prakash , Westwood Thomas , Jaffa Matthew , Fenwick Stephen W. , Nuttall Christina , Lalloo Fiona , Prachalias Andreas , Pizanias Michail , Wieshmann Hulya , McNamara Mairead G. , Hubner Richard , Srirajaskanthan Raj , Vivian Gillian , Ramage John , Weickert Martin O. , Pritchard D Mark , Vinjamuri Sobhan , Valle Juan , Yip Vincent S. 

TITLE=The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours

JOURNAL=Frontiers in Endocrinology

VOLUME=12

YEAR=2021

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.654975

DOI=10.3389/fendo.2021.654975

ISSN=1664-2392

ABSTRACT=<sec><title>Objective</title><p>Pancreatic neuroendocrine tumours (panNETs) arise sporadically or as part of a genetic predisposition syndrome. CT/MRI, endoscopic ultrasonography and functional imaging using Octreoscan localise and stage disease. This study aimed to evaluate the complementary role of <sup>68</sup>Gallium (<sup>68</sup>Ga)-DOTA PET/CT in managing patients with panNETs.</p></sec><sec><title>Design</title><p>A retrospective study conducted across three tertiary UK NET referral centres.</p></sec><sec><title>Methods</title><p>Demographic, clinical, biochemical, cross-sectional and functional imaging data were collected from patients who had undergone a <sup>68</sup>Ga-DOTA PET/CT scan for a suspected panNET.</p></sec><sec><title>Results</title><p>We collected data for 183 patients (97 male): median (SD) age 63 (14.9) years, 89.1 <italic>vs.</italic> 9.3% (n=163 vs. 17) alive <italic>vs.</italic> dead (3 data missing), 141 sporadic <italic>vs.</italic> 42 familial (MEN1, n=36; 85.7%) panNETs. Non-functional <italic>vs.</italic> functional tumours comprised 73.2 <italic>vs.</italic> 21.3% (n=134 <italic>vs.</italic> 39) (10 missing). Histological confirmation was available in 89% of individuals (n=163) but tumour grading (Ki67 classiifcation) was technically possible only in a smaller cohort (n=143): grade 1, 50.3% (n=72); grade 2, 46.2% (n=66) and grade 3, 3.5% (n=5) (40 histopathological classification either not technically feasible or biopsy not perfomed). 60.1% (n=110) were localised, 14.2% (n=26) locally advanced and 23.5% (n=43) metastatic (4 missing). 224 <sup>68</sup>Ga-DOTA PET/CT scans were performed in total for: diagnosis/staging 40% (n=88), post-operative assessment/clinical surveillance 53% (n=117) and consideration of peptide receptor radionuclide therapy (PRRT) 8% (n=17) (2 missing). PET/CT results confirmed other imaging findings (53%), identified new disease sites (28.5%) and excluded suspected disease (5%). Overall, <sup>68</sup>Ga-DOTA PET/CT imaging findings provided additional information in 119 (54%) patients and influenced management in 85 (39%) cases.</p></sec><sec><title>Conclusion</title><p><sup>68</sup>Ga-DOTA PET/CT imaging more accurately stages and guides treatment in patients with sporadic/familial panNETs with newly diagnosed/recurrent disease.</p></sec>